Protagenic Therapeutics (PTIX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Protagenic Therapeutics (PTIX) is down 65.4% since the beginning of the year. At $0 per share, PTIX is trading 92.7% below its 52-week high of $6. Investors who bought $1,000 worth of PTIX shares 5 years ago would now be looking at an investment worth $3.

Protagenic Therapeutics (PTIX) has returned -65.38% so far this year and -87.36% over the past 12 months. Over the last ten years, PTIX has returned -53.06% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jan 5, 2016, PTIX's average daily return is +0.38%, while the average monthly return is +1.15%. At this rate, an investment would double in approximately 5.1 years.

Historically, 27% of months were positive and 73% were negative. The best month was Jan 2016 with a return of +429.4%, while the worst month was Jan 2026 at -63.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, PTIX closed higher 28% of trading days. The best single day was May 19, 2025 with a return of +266.3%, while the worst single day was Jul 15, 2016 at -90.0%.

Protagenic Therapeutics has an annualized alpha of 148.41%, beta of 0.24, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 05, 2016.

• This stock participated in 217.73% of S&P 500 Index downside but only -53.21% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.24 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PTIX ranks 16 for risk / return — in the bottom 16% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Protagenic Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Protagenic Therapeutics was 99.98%, occurring on Feb 17, 2026. The portfolio has not yet recovered.

The current Protagenic Therapeutics drawdown is 99.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Protagenic Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Protagenic Therapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.